UP!

CATB $6.53   View long term graphs

Catabasis Pharmaceuticals
Type
Public
Traded as NASDAQ: CATB
Industry Pharmaceuticals
Headquarters Cambridge, Massachusetts
Key people

Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer and Senior Vice President, Clinical Development) Ted Hibben (Chief Business Officer)

Andrew Nichols, Ph.D. (Chief Scientific Officer)
Products Orally-delivered pharmaceuticals
Number of employees
34 (June 2015)
Website www.catabasis.com

Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer and Senior Vice President, Clinical Development) Ted Hibben (Chief Business Officer)

Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. Catabasis’ SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables the company to engineer molecules that simultaneously modulate multiple targets in a disease. Catabasis is applying their SMART linker platform to build an internal pipeline of product candidates for rare diseases and plans to pursue partnerships to develop additional product candidates.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-06-09 Lower Price Target Citigroup Inc. Buy $16.00 to $8.00
2016-06-08 Reiterated Rating Cowen and Company Buy
2016-06-07 Reiterated Rating Wedbush Outperform $27.00 to $17.00
2016-05-25 Reiterated Rating Oppenheimer Outperform $28.00
2016-05-25 Reiterated Rating Oppenheimer Holdings Inc. Outperform $28.00
2016-05-14 Reiterated Rating Cowen and Company Buy
2016-05-14 Reiterated Rating Oppenheimer Buy
2016-05-13 Reiterated Rating Wedbush Outperform $27.00
2016-03-28 Reiterated Rating Wedbush Outperform $27.00
2016-03-22 Lower Price Target Citigroup Inc. Buy $21.00 to $16.00
2016-03-07 Reiterated Rating Cowen and Company Outperform $30.00
2016-03-02 Reiterated Rating Wedbush Outperform $27.00
2016-01-19 Reiterated Rating Wedbush Outperform $27.00
2016-01-04 Reiterated Rating Wedbush Outperform $27.00
2015-12-11 Initiated Coverage Wedbush Buy
2015-12-10 Reiterated Rating Wedbush Outperform $27.00
2015-08-17 Reiterated Rating Wedbush Buy $27.00
2015-07-20 Initiated Coverage Oppenheimer Positive to Outperform $28.00
2015-07-20 Initiated Coverage Citigroup Inc. Buy $21.00
2015-07-20 Initiated Coverage Cowen and Company Outperform $30.00
2015-07-20 Initiated Coverage Wedbush Outperform $27.00
2016-06-09 Lower Price Target Citigroup Inc. Buy $16.00 to $8.00
2016-06-08 Reiterated Rating Cowen and Company Buy
2016-06-07 Reiterated Rating Wedbush Outperform $27.00 to $17.00
2016-05-25 Reiterated Rating Oppenheimer Outperform $28.00
2016-05-25 Reiterated Rating Oppenheimer Holdings Inc. Outperform $28.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments